This article is more than 5 years old. Information may no longer be current.

Eyenovia proposes public stock offering

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyenovia will offer and sell shares of its common stock in an underwritten public offering, using the proceeds to fund its MicroProst and MicroPine clinical studies, the company announced.

The underwriters are expected to be granted a 30-day option to purchase an additional 15% of the shares to be sold in the offering, which is subject to market and other conditions, according to a press release.

Eyenovia’s MicroProst, a treatment candidate for chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, and its myopia treatment candidate MicroPine are both in phase 3 development.

Oppenheimer & Co. Inc. is the offering’s sole book-running manager, with Ladenburg Thalmann & Co. Inc. acting as lead manager, the release said.